Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Quarterly research and development and administrative expenses increased, while ATM share sales generated $15.7 million in net proceeds.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) reported a third-quarter 2026 net loss of $53.9 million and provided updates on its gene-therapy trials. The loss widened from $45.8 million a year earlier. Cash, cash equivalents and available-for-sale securities totaled $348.9 million at September 30; Solid expects funding to last into H1 2028.
SGT-003 was generally well tolerated in 53 INSPIRE DUCHENNE participants as of November 3. A late-Q4 2026 FDA meeting will seek guidance on a potential accelerated approval pathway; Phase 3 IMPACT DUCHENNE dosing is ongoing. Five SGT-212 participants had no treatment-related serious adverse events as of November 3. Solid expects initial data in Q1 2027, subject to enrollment; the therapy received European Commission Orphan designation in October. SGT-501 trial screening has begun, with first dosing expected by year-end 2026 and initial safety data in H1 2027, subject to enrollment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCash and securities of $348.9 million at September 30, 2026, increased from $187.9 million at December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Operational runway is expected to extend into the first half of 2028.
- Moderate pointATM share sales generated $15.7 million in net proceeds during Q3 2026. 2.3% of market cap
- Minor pointSGT-003 was generally well tolerated in 53 INSPIRE DUCHENNE participants as of November 3, 2026.
- Minor pointIMPACT DUCHENNE Phase 3 dosing began in Q2 2026; screening and enrollment remain ongoing.
9 minor points
- Minor pointSGT-212 had no treatment-related serious adverse events among five dosed participants as of November 3, 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.SGT-212 initial data are expected in Q1 2027, subject to participant enrollment.
- Minor pointSGT-212 Orphan designation was granted by the European Commission in October for Friedreich’s ataxia.
- Minor pointSGT-501 trial sites are activated, and Phase 1b ARTEMIS participant screening has commenced.
- Minor point. Forward-looking: it has not happened yet and may not happen.SGT-501 first dosing is expected by year-end 2026, with initial safety data anticipated in H1 2027, subject to enrollment.
- Minor pointPOLARIS-101 agreements exceed 50, including licenses, with corporations, institutions and academic labs.
- Minor pointNet loss per share narrowed to $0.36 from $0.48 in Q3 and $1.23 from $1.46 over nine months, year over year.
- Minor pointInterest income increased to $3.343 million from $2.586 million in Q3 2026 versus Q3 2025.
- Minor pointNine-month interest income increased to $8.628 million in 2026 from $7.852 million in 2025.
Negative
- Moderate pointQ3 net loss widened to $53.948 million in 2026 from $45.776 million in 2025.
- Moderate pointQ3 R&D expenses increased to $43.595 million in 2026 from $38.861 million in 2025.
- Moderate pointQ3 administrative expenses increased to $14.060 million in 2026 from $9.197 million in 2025.
- Moderate pointATM common-stock issuance diluted existing holders during Q3 2026.
- Minor pointNine-month net loss widened to $165.484 million in 2026 from $124.538 million in 2025.
4 minor points
- Minor pointNine-month R&D expenses increased to $134.000 million in 2026 from $102.190 million in 2025.
- Minor pointNine-month administrative expenses increased to $38.347 million in 2026 from $27.613 million in 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.SGT-003 accelerated approval pathway remains potential; FDA guidance will be sought at a late-Q4 2026 meeting.
- Minor point. Forward-looking: it has not happened yet and may not happen.Participant enrollment conditions the SGT-212 initial-data timeline and SGT-501 dosing and initial-safety-data timelines.
News Explained
At September 30, 111,555,073 shares were outstanding; the higher count reduces existing holders’ ownership percentages absent offsets.
Solid reported
An at-the-market program lets an issuer sell new shares gradually into the open market at prevailing prices.
Details
Market Reaction – SLDB
On Nov 4, the day this news came out, the latest delayed price for SLDB is 1.62% above the previous close. Our momentum scanner has recorded 9 alerts for this stock so far that day. The latest delayed price is $6.63.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Cash and securities
- $348.9 million
- As of September 30, 2026
- Cash runway
- Into H1 2028
- Company expectation
- ATM net proceeds
- $15.7 million
- Third quarter 2026
- R&D expenses
- $43.6 million
- Third quarter 2026
- G&A expenses
- $14.1 million
- Third quarter 2026
- Net loss
- $53.9 million
- Third quarter 2026
- INSPIRE DUCHENNE participants dosed
- 53 participants
- Phase 1/2 trial; generally well tolerated as of November 3, 2026
- Type C FDA meeting
- Late Q4 2026
- Discussion of preliminary SGT-003 data and a potential accelerated approval pathway
Previous Earnings Reports
-
Reported $377.7 million in liquidity, 53 SGT-003 participants, two SGT-212 participants, and a $54.8 million net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
accelerated approval regulatory
orphan designation regulatory
at-the-market financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -
- Solid has scheduled a Type C meeting with the FDA in late Q4 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -
- IMPACT DUCHENNE, a Phase 3 placebo-controlled, randomized, double-blind clinical trial, commenced dosing in Q2 2026 and is ongoing -
- Friedreich’s Ataxia (SGT-212): Five participants have been dosed in the Phase 1b FALCON clinical trial and SGT-212 has been well tolerated as of November 3, 2026 -
- Capital Position: Cash, cash equivalents and available-for-sale securities of
CHARLESTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
Bo Cumbo, President and CEO of Solid Biosciences, stated: “As we approach key regulatory and clinical catalysts in our Duchenne and Friedreich’s ataxia programs, our progress this quarter reflects the dedication of our team, the differentiated nature of our clinical programs and the strength of our delivery technologies. In Duchenne, we look forward to meeting with the FDA late in the fourth quarter of 2026 to discuss a potential accelerated approval pathway for SGT-003. Our clearly differentiated safety data are central to those discussions. Across 53 participants dosed in INSPIRE DUCHENNE, SGT-003 has demonstrated an encouraging safety profile using a low-burden, steroid-only immunomodulation regimen. The Duchenne community deserves continued progress on both efficacy and safety, and that is what we are working to deliver.
"In Friedreich's ataxia, we have dosed five participants in the FALCON trial, and SGT-212 recently received Orphan designation from the European Commission. While cardiac disease remains the leading cause of mortality in FA, the FA patient community has consistently told us that slowing the relentless neurologic decline is their top priority. SGT-212 is designed to address both manifestations of the disease, and we believe its dual-route administration is what may uniquely enable SGT-212 to address the full scope of the disease. We anticipate reporting initial data in the first quarter of 2027,” Mr. Cumbo concluded.
Company Updates
Neuromuscular Pipeline
SGT-003 Next-Generation Duchenne Muscular Dystrophy (Duchenne) Program
- SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026. Solid has scheduled a Type C meeting with the FDA late in the fourth quarter of 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003; Solid expects to provide an update following receipt of formal meeting minutes.
- Dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in the second quarter of 2026; participant screening and enrollment remain ongoing.
SGT-212 for Friedreich’s ataxia (FA)
- Five participants have been dosed with SGT-212 in the Phase 1b FALCON clinical trial, with no treatment-related serious adverse events observed as of November 3, 2026.
- Participant screening and enrollment remain ongoing, and Solid expects to report initial data in the first quarter of 2027, subject to participant enrollment.
- In October, SGT-212 received Orphan designation for the treatment of Friedreich’s ataxia from the European Commission, acting upon the positive opinion of the European Medicines Agency’s Committee for Orphan Medicinal Products.
Cardiac Pipeline
SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT)
- Solid has activated clinical trial sites and commenced participant screening for the Phase 1b ARTEMIS clinical trial.
- Solid expects to dose the first participant by the end of 2026, with initial safety data anticipated in the first half of 2027, subject to participant enrollment.
Platform Technologies
- Solid has executed more than 50 agreements, including licenses, with corporations, institutions and academic labs for the use of POLARIS-101TM, the Company’s next-generation, muscle-tropic capsid used in SGT-003.
Third Quarter 2026 Financial Highlights
- Cash Position: Solid had
$348.9 million in cash, cash equivalents and available-for-sale securities as of September 30, 2026, compared to$187.9 million as of December 31, 2025. The Company expects that its existing cash, cash equivalents and available-for-sale securities will be sufficient to fund its operational runway into the first half of 2028. - At-the-Market (ATM) Proceeds: Solid generated
$15.7 million in net proceeds from ATM sales for the third quarter of 2026. - Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2026 were
$43.6 million , compared to$38.9 million for the third quarter of 2025. The increase of$4.7 million was primarily due to a$2.8 million increase in personnel related expenses, a$2.6 million increase in costs for SGT-212 related to manufacturing and clinical costs, a$2.0 million increase in costs for SGT-003 related to manufacturing and research costs, and a$0.6 million increase in other development programs related to internal research costs, partially offset by a$1.6 million decrease in costs for SGT-601 due to lower manufacturing and internal research costs, a$1.1 million decrease in external expenses related to lower lab and professional service costs, and a$0.7 million decrease in costs for SGT-501 due to lower clinical and internal research costs. - General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2026 were
$14.1 million , compared to$9.2 million for the third quarter of 2025. The increase of$4.9 million was primarily due to a$2.8 million increase in personnel related costs, a$0.8 million increase in costs related to commercial readiness, a$0.5 million increase in consulting and professional services, a$0.4 million increase in information technology and equipment related costs, and a$0.3 million increase in finance and legal expenses. - Net Loss: Net loss for the third quarter of 2026 was
$53.9 million , compared to a net loss of$45.8 million for the third quarter of 2025.
About SGT-003
SGT-003 is an investigational gene therapy containing a novel microdystrophin construct and a proprietary, next-generation capsid, POLARIS-101 (formerly known as AAV-SLB101), which was rationally designed to target integrin receptors, and has shown enhanced cardiac and skeletal muscle transduction with decreased liver targeting in data from the Phase 1/2 INSPIRE DUCHENNE clinical trial and in nonclinical studies. SGT-003’s microdystrophin construct uniquely includes the R16/17 domains, which localize nNOS to the muscle. Nonclinical studies have shown that nNOS can improve blood flow to the muscle, thereby reducing muscle breakdown from ischemia and muscle fatigue. Together, these design features suggest that SGT-003 could be a potential best-in-class investigational gene therapy for the treatment of Duchenne.
About the SGT-003 Development Program
The SGT-003 clinical development program consists of two multinational clinical trials – the Phase 1/2 INSPIRE DUCHENNE trial (NCT06138639) and the Phase 3 IMPACT DUCHENNE trial (NCT07160634) – which together were designed to generate a comprehensive data package to support potential global regulatory authorizations.
INSPIRE DUCHENNE is a first-in-human, open-label, single-dose, multicenter Phase 1/2 clinical trial evaluating the safety, tolerability and efficacy of a single dose of SGT-003 in pediatric participants with a genetically confirmed Duchenne diagnosis. The trial is being conducted at clinical sites in the United States, Canada, the United Kingdom and Italy.
IMPACT DUCHENNE is a Phase 3 placebo-controlled, randomized, double-blind clinical trial evaluating the efficacy of a single dose of SGT-003 in ambulatory participants with a genetically confirmed Duchenne diagnosis. The trial is expected to be conducted in Canada, Australia, the United States and multiple countries in Europe.
About SGT-212
SGT-212 is a recombinant AAV-based gene replacement therapy for Friedreich’s ataxia (FA) designed to deliver full-length human frataxin (FXN) via a dual route of administration: intradentate nucleus (IDN) infusion, using an FDA-approved neurosurgical device in a stereotactic, precision MRI-guided technique, followed by an intravenous (IV) infusion, with the intent to increase therapeutic FXN levels in the cerebellar dentate nuclei, cardiomyocytes and other systemic tissues. Targeted delivery to the dentate nuclei will be confirmed in real time via MRI. Restoration of FXN levels is expected to repair the underlying mitochondrial dysfunction in neurons and cardiomyocytes to address neurologic, cardiac and systemic manifestations of the disease.
About the FALCON Clinical Trial
FALCON is a first-in-human, open-label, multicenter Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been diagnosed with FA. FALCON is being conducted in the United States.
About POLARIS-101™
POLARIS-101 (formerly AAV-SLB101) is Solid’s proprietary, next-generation, rationally engineered capsid developed for enhanced skeletal and cardiac muscle tropism and reduced liver biodistribution. Preclinical studies have demonstrated increased transduction speed, enhanced skeletal and cardiac muscle delivery, decreased liver biodistribution and improved efficiency compared with first-generation capsid benchmarks. POLARIS-101 is being clinically evaluated as the delivery capsid for SGT-003, Solid’s investigational gene therapy for Duchenne muscular dystrophy, in the Phase 1/2 INSPIRE DUCHENNE clinical trial (NCT06138639) and the Phase 3 IMPACT DUCHENNE clinical trial (NCT07160634).
POLARIS-101 is part of Solid’s broader gene therapy technology platform that includes proprietary manufacturing and other enabling delivery technologies, such as additional capsids and promoters. This expanded platform has been developed to provide next-generation technologies to developers early in the research and development cycle when technology decisions can shape the long-term performance of a program.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com and follow us on LinkedIn at Solid Biosciences and X at @Solid_Bio.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company’s goals; anticipated benefits of SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs and technologies; strategies and expectations for the company’s SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs and technologies; expectations for planned site activation, planned enrollment, planned regulatory interactions and the potential approval pathways for SGT-003, SGT-212, SGT-501 and SGT-601; the cash runway of the company and the sufficiency of the Company’s cash, cash equivalents and available-for-sale securities to fund its operations; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to advance SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs, capsid libraries and other enabling technologies on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company’s product candidates; manufacture sufficient quantities of our drug product in a timely manner and maintain adequate supply to support our clinical development and potential commercialization; obtain, maintain or protect intellectual property rights related to its product candidates; replicate preliminary or interim data from clinical trials in the final data of such trials; compete successfully with other companies that are seeking to develop Duchenne, FA, CPVT and other neuromuscular and cardiac treatments and gene therapies; manage expenses; raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003, SGT-212, SGT-501, SGT-601 and other candidates; and achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.
Investor Contact
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact
Amir Khan
Corporate Affairs Practice
Syneos Health
amir.khan@syneoshealth.com
(347) 249-0230
| SOLID BIOSCIENCES, INC | ||||||
| SELECTED FINANCIAL INFORMATION (UNAUDITED) | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | September 30, | December 31, | ||||
| (in thousands, except share data) | 2026 | 2025 | ||||
| Cash and cash equivalents | $ | 125,971 | $ | 59,900 | ||
| Available-for-sale securities | 222,957 | 127,950 | ||||
| Prepaid expenses and other current assets | 15,629 | 16,384 | ||||
| Restricted cash, current | 638 | 1,222 | ||||
| Operating lease, right-of-use assets | 20,020 | 21,924 | ||||
| Property and equipment, net | 3,734 | 4,169 | ||||
| Other non-current assets | 248 | 223 | ||||
| Restricted cash, net of current portion | 708 | 768 | ||||
| Total assets | $ | 389,905 | $ | 232,540 | ||
| Accounts payable | $ | 3,230 | $ | 3,224 | ||
| Accrued expenses and other current liabilities | 20,890 | 18,945 | ||||
| Operating lease liabilities, current | 2,284 | 2,103 | ||||
| Derivative liabilities | 4,050 | 9,200 | ||||
| Operating lease liabilities, net of current portion | 17,340 | 19,058 | ||||
| Total stockholders’ equity | 342,111 | 180,010 | ||||
| Total liabilities and stockholders’ equity | $ | 389,905 | $ | 232,540 | ||
| Common stock outstanding | 111,555,073 | 78,967,888 | ||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| (in thousands, except per share data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 43,595 | $ | 38,861 | $ | 134,000 | $ | 102,190 | ||||||||
| General and administrative | 14,060 | 9,197 | 38,347 | 27,613 | ||||||||||||
| Total operating expenses | 57,655 | 48,058 | 172,347 | 129,803 | ||||||||||||
| Loss from operations | (57,655 | ) | (48,058 | ) | (172,347 | ) | (129,803 | ) | ||||||||
| Other income, net: | ||||||||||||||||
| Interest income | 3,343 | 2,586 | 8,628 | 7,852 | ||||||||||||
| Interest expense | — | 336 | — | 208 | ||||||||||||
| Change in fair value of derivative liabilities | 150 | (850 | ) | (2,350 | ) | (3,400 | ) | |||||||||
| Other income, net | 214 | 210 | 585 | 605 | ||||||||||||
| Total other income, net | 3,707 | 2,282 | 6,863 | 5,265 | ||||||||||||
| Net loss | $ | (53,948 | ) | $ | (45,776 | ) | $ | (165,484 | ) | $ | (124,538 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.36 | ) | $ | (0.48 | ) | $ | (1.23 | ) | $ | (1.46 | ) | ||||
| Weighted average shares of common stock outstanding, basic and diluted | 151,031,642 | 94,417,746 | 134,994,925 | 85,069,288 | ||||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Solid Biosciences’ Q3 2026 financial results and cash runway?
Solid Biosciences reported a $53.9 million net loss for Q3 2026, compared with $45.8 million a year earlier. Cash, cash equivalents and available-for-sale securities totaled $348.9 million at September 30, 2026. The company expects its existing funds to support operations into the first half of 2028.
What is the next FDA milestone for Solid Biosciences’ SGT-003?
A Type C FDA meeting is scheduled for late Q4 2026 to discuss the preliminary INSPIRE DUCHENNE data package and seek guidance on a potential accelerated approval pathway. Solid expects to provide an update after receiving formal meeting minutes.